Gene Gene synonym Ensembl Gene description Chromosome Position Protein class Evidence Antibody Reliability (IH) Reliability (Mouse Brain) Reliability (IF) Subcellular location Prognostic p-value RNA cancer category RNA tissue category RNA TS RNA TS TPM TPM max in non-specific MMP26 endometase, MGC126590, MGC126592 ENSG00000167346 Matrix metallopeptidase 26 11 4704927-4992429 Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at transcript level Group enriched Tissue enriched 64 endometrium: 23.8 prostate,testis: 0.3 IGFBP1 AFBP, hIGFBP-1, IBP1, IGF-BP25, PP12 ENSG00000146678 Insulin-like growth factor binding protein 1 7 45888357-45893668 Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB004445, HPA046972, HPA050640 Supported Approved Golgi apparatus Renal cancer:6.90e-11 (unfavourable), Lung cancer:1.03e-4 (unfavourable), Stomach cancer:6.64e-4 (unfavourable) Tissue enriched Group enriched 53 endometrium: 120.4;liver: 562.2;placenta: 264.8 fallopian tube: 5.9 MMP10 STMY2 ENSG00000166670 Matrix metallopeptidase 10 11 102770503-102780628 Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level CAB002159 Uncertain Approved Plasma membrane
Cytosol Urothelial cancer:7.12e-4 (favourable) Tissue enhanced Tissue enriched 39 endometrium: 443.1 appendix: 11.3 TEX15 CT42 ENSG00000133863 Testis expressed 15 8 30831544-30890606 Predicted intracellular proteins Evidence at transcript level HPA036799, HPA036800 Approved Approved Nuclear speckles Not detected Group enriched 31 endometrium: 10.9;smooth muscle: 8.2;testis: 22.2 cerebral cortex,gallbladder: 0.4 ADAMTS19 ENSG00000145808 ADAM metallopeptidase with thrombospondin type 1 motif, 19 5 129460265-129738683 Enzymes, Predicted secreted proteins Evidence at transcript level HPA056171, HPA058438 Uncertain Approved Vesicles
Midbody Tissue enhanced Group enriched 13 cervix, uterine: 16.4;endometrium: 16.4;placenta: 5.2;smooth muscle: 8.9 adrenal gland: 0.9 GPR22 ENSG00000172209 G protein-coupled receptor 22 7 107470018-107475659 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level Not detected Group enriched 13 adrenal gland: 2.4;cerebral cortex: 9.5;cervix, uterine: 6.3;endometrium: 5.0;heart muscle: 11.9 smooth muscle: 0.5 CHRDL2 BNF1 ENSG00000054938 Chordin-like 2 11 74696429-74731385 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA021771 Uncertain Uncertain Mitochondria Urothelial cancer:6.08e-4 (unfavourable) Tissue enhanced Group enriched 9 appendix: 162.3;endometrium: 128.0;gallbladder: 169.0;smooth muscle: 181.2;urinary bladder: 45.0 cervix, uterine: 14.5 MMP11 STMY3 ENSG00000099953 Matrix metallopeptidase 11 22 23768226-23784316 Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level CAB002593, HPA068864 Approved Renal cancer:2.62e-4 (unfavourable) Expressed in all Group enriched 9 cervix, uterine: 30.9;endometrium: 122.3;placenta: 27.9 smooth muscle: 6.4 TRH ENSG00000170893 Thyrotropin-releasing hormone 3 129974305-129977938 Predicted secreted proteins Evidence at protein level HPA035595, HPA035596 Approved Tissue enhanced Group enriched 9 cervix, uterine: 31.9;endometrium: 27.4 fallopian tube: 3.3 ESR1 Era, ESR, NR3A1 ENSG00000091831 Estrogen receptor 1 6 151656691-152129619 Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB000037, HPA000449, HPA000450, CAB055099, CAB072858 Supported Approved Nucleus
Vesicles Endometrial cancer:5.47e-7 (favourable) Group enriched Group enriched 8 breast: 37.4;cervix, uterine: 127.3;endometrium: 179.7;fallopian tube: 105.5;smooth muscle: 75.9 seminal vesicle: 13.5 PRL ENSG00000172179 Prolactin 6 22287244-22297501 Cancer-related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB023353, HPA042416, HPA062017 Supported Uncertain Cytosol Not detected Group enriched 8 endometrium: 10.7;placenta: 27.1 testis: 2.2 ZCCHC12 FLJ16123, PNMA7A, SIZN, SIZN1 ENSG00000174460 Zinc finger, CCHC domain containing 12 X 118823790-118826968 Predicted intracellular proteins Evidence at protein level HPA031016, HPA034940 Uncertain Approved Nuclear bodies Thyroid cancer:3.42e-5 (favourable) Tissue enriched Group enriched 8 endometrium: 165.7;fallopian tube: 182.3;smooth muscle: 201.4 cerebral cortex: 24.4 PAEP GD, GdA, GdF, GdS, MGC138509, MGC142288, PAEG, PEP, PP14 ENSG00000122133 Progestagen-associated endometrial protein 9 135561756-135566955 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB016762, HPA020108, HPA029473 Supported Renal cancer:0.00e+0 (unfavourable), Liver cancer:6.61e-6 (unfavourable), Stomach cancer:5.46e-4 (unfavourable) Tissue enriched Tissue enriched 7 endometrium: 437.4 seminal vesicle: 60.8 PRLHR GPR10, PrRPR ENSG00000119973 Prolactin releasing hormone receptor 10 118589989-118595699 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA039361 Supported Not detected Group enriched 7 adrenal gland: 6.5;cerebral cortex: 3.5;endometrium: 3.9;smooth muscle: 5.4 seminal vesicle: 0.7 PTGER3 EP3 ENSG00000050628 Prostaglandin E receptor 3 (subtype EP3) 1 70852353-71047808 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA010689 Uncertain Renal cancer:3.50e-4 (unfavourable) Group enriched Group enriched 7 adipose tissue: 58.5;endometrium: 114.7;kidney: 87.6;smooth muscle: 103.9 skin: 14.0 AGTR2 AT2, MRX88 ENSG00000180772 Angiotensin II receptor, type 2 X 116170722-116174972 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level Group enriched Group enriched 6 cervix, uterine: 6.8;endometrium: 13.8;fallopian tube: 3.8;lung: 12.6;smooth muscle: 17.4 adrenal gland: 1.9 ANO4 FLJ34221, FLJ34272, FLJ35277, TMEM16D ENSG00000151572 Anoctamin 4 12 100717526-101128641 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA053412 Uncertain Renal cancer:5.48e-5 (favourable) Mixed Group enriched 6 adrenal gland: 17.6;cerebral cortex: 10.0;cervix, uterine: 12.5;endometrium: 8.3;ovary: 10.9;prostate: 10.9;seminal vesicle: 11.3 testis: 2.0 ASIC2 ACCN, ACCN1, ASIC2a, BNaC1, BNC1, hBNaC1, MDEG ENSG00000108684 Acid sensing (proton gated) ion channel 2 17 33013087-34174964 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA052112 Approved Tissue enhanced Group enriched 6 cerebral cortex: 8.7;cervix, uterine: 3.9;endometrium: 6.4;smooth muscle: 2.1 adrenal gland: 0.8 CDC20B FLJ37927 ENSG00000164287 Cell division cycle 20B 5 55112995-55173175 Predicted intracellular proteins Evidence at protein level HPA053900 Uncertain Tissue enhanced Group enriched 6 endometrium: 1.2;fallopian tube: 3.4;kidney: 1.2;testis: 4.7 lung: 0.4 IGFN1 DKFZp434B1231, EEF1A2BP1 ENSG00000163395 Immunoglobulin-like and fibronectin type III domain containing 1 1 201190825-201228952 Predicted intracellular proteins Evidence at protein level HPA050415 Supported Approved Midbody ring Renal cancer:1.27e-8 (unfavourable) Group enriched Group enriched 6 endometrium: 17.1;epididymis: 18.1;skeletal muscle: 60.2 cerebral cortex: 5.6 IHH BDA1, HHG2 ENSG00000163501 Indian hedgehog 2 219054420-219060467 Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level Endometrial cancer:3.67e-6 (favourable) Tissue enhanced Group enriched 6 cervix, uterine: 8.8;colon: 21.4;duodenum: 15.3;endometrium: 31.4;rectum: 16.9;small intestine: 16.8;stomach: 15.6 appendix,prostate: 3.1 IL17C CX2, IL-17C, IL-21, MGC126884, MGC138401 ENSG00000124391 Interleukin 17C 16 88638591-88640473 Predicted secreted proteins Evidence at protein level HPA065051 Supported Mixed Tissue enriched 6 endometrium: 3.5 gallbladder: 0.6 LEFTY2 EBAF, LEFTA, LEFTYA, TGFB4 ENSG00000143768 Left-right determination factor 2 1 225936598-225941489 Disease related genes, Predicted secreted proteins Evidence at protein level CAB025801, HPA047883, HPA056210 Approved Tissue enriched Group enriched 6 endometrium: 270.5;smooth muscle: 56.3 ovary: 26.0 MSX1 HOX7, HYD1, OFC5 ENSG00000163132 Msh homeobox 1 4 4859666-4863936 Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB026198, HPA063895, HPA073604 Supported Supported Nucleoplasm Endometrial cancer:1.64e-7 (favourable), Renal cancer:1.18e-5 (unfavourable) Tissue enriched Group enriched 6 cervix, uterine: 60.9;endometrium: 23.8 adipose tissue: 6.7 PGR NR3C3, PR ENSG00000082175 Progesterone receptor 11 101029624-101130524 Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB000068, HPA004751, HPA008428, HPA017176, CAB055100 Supported Endometrial cancer:5.76e-8 (favourable) Group enriched Group enriched 6 cervix, uterine: 95.8;endometrium: 171.3;fallopian tube: 52.8;smooth muscle: 113.5 ovary: 19.4 SLC46A2 Ly110, TSCOT ENSG00000119457 Solute carrier family 46, member 2 9 112878920-112890913 Predicted membrane proteins, Transporters Evidence at transcript level HPA020098 Approved Tissue enhanced Group enriched 6 cervix, uterine: 23.0;endometrium: 5.5;epididymis: 5.4;lung: 15.2;skin: 11.3 seminal vesicle: 2.0 WNT2 INT1L1, IRP ENSG00000105989 Wingless-type MMTV integration site family member 2 7 117276631-117323289 Cancer-related genes, Predicted secreted proteins Evidence at protein level HPA020920 Approved Vesicles Mixed Group enriched 6 endometrium: 23.6;placenta: 92.5 lung: 9.2 EMX2 ENSG00000170370 Empty spiracles homeobox 2 10 117542444-117549546 Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA003497, HPA065294 Approved Supported Approved Nucleus Renal cancer:2.28e-13 (favourable), Cervical cancer:2.80e-4 (favourable) Group enriched Group enriched 5 cervix, uterine: 59.4;endometrium: 114.7;epididymis: 113.9;fallopian tube: 72.9;kidney: 38.3;seminal vesicle: 64.9;smooth muscle: 59.6 cerebral cortex: 14.0 SFRP4 FRP-4, frpHE ENSG00000106483 Secreted frizzled-related protein 4 7 37905932-38025695 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA009712, HPA050585 Supported Renal cancer:1.36e-5 (unfavourable) Expressed in all Group enriched 5 cervix, uterine: 931.0;endometrium: 772.5;fallopian tube: 335.6 smooth muscle: 129.2 TMEM215 ENSG00000188133 Transmembrane protein 215 9 32783499-32787399 Predicted membrane proteins Evidence at transcript level HPA052804 Uncertain Tissue enriched Group enriched 5 cervix, uterine: 1.0;endometrium: 4.8;testis: 4.2;thyroid gland: 1.8 cerebral cortex: 0.5 AC066615.1 ENSG00000259752 15 47133652-47134026 Predicted intracellular proteins Evidence at transcript level HPA042797 Uncertain Not detected Tissue enhanced endometrium: 2.1;urinary bladder: 1.7 esophagus: 1.4 AC074033.1 ENSG00000281137 3 169483709-169483946 Predicted intracellular proteins Evidence at transcript level Not detected Tissue enhanced endometrium: 2.0 thyroid gland: 0.9 ADAMTS7 ADAM-TS7, DKFZp434H204 ENSG00000136378 ADAM metallopeptidase with thrombospondin type 1 motif, 7 15 78759203-78811431 Enzymes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA045284, HPA048453 Uncertain Approved Vesicles Stomach cancer:9.53e-4 (unfavourable) Mixed Tissue enhanced endometrium: 7.2 heart muscle: 4.7 ADAMTSL1 ADAMTSR1, C9orf94, FLJ35283 ENSG00000178031 ADAMTS-like 1 9 18473894-18910950 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA057437 Uncertain Mixed Tissue enhanced endometrium: 20.7 smooth muscle: 16.1 ADRA2C ADRA2L2, ADRA2RL2, ADRARL2 ENSG00000184160 Adrenoceptor alpha 2C 4 3766348-3768526 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA057688 Uncertain Mixed Tissue enhanced cervix, uterine: 21.0;endometrium: 26.0;seminal vesicle: 26.7 fallopian tube: 7.9 ALDH1A2 RALDH2 ENSG00000128918 Aldehyde dehydrogenase 1 family, member A2 15 57953424-58497866 Enzymes, Predicted intracellular proteins Evidence at protein level HPA010022 Approved Mixed Tissue enhanced endometrium: 117.2;fallopian tube: 107.1 testis: 96.5 AP000349.2 ENSG00000280178 22 23782283-23783958 Predicted intracellular proteins Evidence at transcript level Not detected Tissue enhanced cervix, uterine: 2.2;endometrium: 4.0 smooth muscle: 1.6 ASPN FLJ20129, PLAP1, SLRR1C ENSG00000106819 Asporin 9 92456205-92482506 Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA008435, HPA024230 Approved Supported Nucleoplasm
Vesicles Renal cancer:1.64e-7 (unfavourable) Expressed in all Tissue enhanced endometrium: 114.7;smooth muscle: 159.0 gallbladder: 104.4 BNC2 BSN2, FLJ20043 ENSG00000173068 Basonuclin 2 9 16409503-16870843 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA018525 Approved Supported Nucleus
Cytosol Mixed Tissue enhanced endometrium: 44.4;ovary: 39.3;smooth muscle: 47.3 fallopian tube: 19.3 C1QTNF6 CTRP6, ZACRP6 ENSG00000133466 C1q and tumor necrosis factor related protein 6 22 37180167-37199385 Predicted intracellular proteins Evidence at protein level HPA002042 Supported Approved Nucleus Renal cancer:0.00e+0 (unfavourable), Lung cancer:9.60e-6 (unfavourable) Expressed in all Tissue enhanced endometrium: 52.2;placenta: 41.1 gallbladder: 13.5 CDH13 CDHH ENSG00000140945 Cadherin 13 16 82626803-83800640 Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA001380, CAB025863 Supported Supported Plasma membrane Renal cancer:1.73e-6 (unfavourable) Expressed in all Tissue enhanced endometrium: 82.5 cervix, uterine: 72.5 CEMIP IR2155535, KIAA1199, TMEM2L ENSG00000103888 Cell migration inducing protein, hyaluronan binding 15 80779343-80951776 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level Urothelial cancer:2.65e-4 (unfavourable) Expressed in all Tissue enhanced endometrium: 54.5 epididymis: 17.0 CPXM1 CPX-1, CPX1, CPXM ENSG00000088882 Carboxypeptidase X (M14 family), member 1 20 2794069-2800637 Enzymes, Predicted secreted proteins Evidence at protein level Renal cancer:4.62e-10 (unfavourable) Expressed in all Tissue enhanced endometrium: 130.2;gallbladder: 132.9 urinary bladder: 77.4 CTC-273B12.7 ENSG00000268465 19 48465837-48472431 Predicted intracellular proteins Evidence at transcript level Not detected Tissue enhanced colon: 1.2;endometrium: 1.3;testis: 2.8 small intestine: 0.6 CYP24A1 CP24, CYP24, P450-CC24 ENSG00000019186 Cytochrome P450, family 24, subfamily A, polypeptide 1 20 54153449-54173973 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA022261, HPA063771 Supported Supported Nucleoplasm
Plasma membrane
Mitochondria Mixed Tissue enhanced endometrium: 24.8;urinary bladder: 52.7 placenta: 13.9 DLX5 ENSG00000105880 Distal-less homeobox 5 7 97020392-97025097 Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA005670 Approved Uncertain Nucleus Tissue enriched Tissue enhanced endometrium: 20.1;placenta: 13.5;skin: 17.2 cervix, uterine: 9.5 DLX6 ENSG00000006377 Distal-less homeobox 6 7 97005548-97011039 Predicted intracellular proteins, Transcription factors Evidence at transcript level HPA030608, HPA061460 Uncertain Approved Nuclear bodies Tissue enriched Tissue enhanced endometrium: 4.4;placenta: 4.3;testis: 5.4 cervix, uterine: 3.0 DPP6 DPPX ENSG00000130226 Dipeptidyl-peptidase 6 7 153887097-154894285 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA050509 Supported Supported Tissue enriched Tissue enhanced cerebral cortex: 51.2;endometrium: 27.4 smooth muscle: 15.2 EPO EP ENSG00000130427 Erythropoietin 7 100720800-100723700 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Predicted secreted proteins Evidence at protein level CAB010336 Supported Renal cancer:2.18e-6 (unfavourable), Liver cancer:5.67e-5 (unfavourable) Group enriched Tissue enhanced cervix, uterine: 2.0;endometrium: 1.7;liver: 1.7 prostate: 1.1 FAP DPPIV ENSG00000078098 Fibroblast activation protein, alpha 2 162170684-162245151 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA059739 Approved Head and neck cancer:4.82e-4 (unfavourable) Mixed Tissue enhanced endometrium: 50.4 smooth muscle: 37.9 FBXL22 Fbl22, FLJ39626 ENSG00000197361 F-box and leucine-rich repeat protein 22 15 63597353-63602428 Predicted intracellular proteins Evidence at protein level HPA047624, HPA054627 Uncertain Uncertain Nucleoli
Cytosol Mixed Tissue enhanced endometrium: 45.1;seminal vesicle: 34.9;smooth muscle: 36.2 prostate: 17.4 FOXL2 BPES, BPES1 ENSG00000183770 Forkhead box L2 3 138944224-138947140 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA069613 Supported Supported Nucleus
Cytokinetic bridge Mixed Tissue enhanced endometrium: 12.1;ovary: 29.6;parathyroid gland: 24.2 fallopian tube: 7.6 FOXL2NB C3orf72, FLJ43329 ENSG00000206262 FOXL2 neighbor 3 138947234-138953451 Predicted intracellular proteins Evidence at protein level HPA061017, HPA071790 Supported Nucleoli fibrillar center Mixed Tissue enhanced endometrium: 29.1;ovary: 50.7;parathyroid gland: 63.1 fallopian tube: 19.5 FREM1 C9orf143, C9orf145, C9orf154, DKFZp686M16108, FLJ25461, TILRR ENSG00000164946 FRAS1 related extracellular matrix 1 9 14734666-14910995 Disease related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level Mixed Tissue enhanced endometrium: 33.8;epididymis: 43.7 smooth muscle: 22.8 FRMD7 FLJ43346, NYS, NYS1 ENSG00000165694 FERM domain containing 7 X 132076993-132128020 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA000886 Uncertain Not detected Tissue enhanced endometrium: 2.8;kidney: 3.0;smooth muscle: 3.4 seminal vesicle: 0.7 GAL3ST3 GAL3ST2 ENSG00000175229 Galactose-3-O-sulfotransferase 3 11 66041952-66049180 Predicted secreted proteins Evidence at protein level Endometrial cancer:6.53e-6 (unfavourable) Tissue enhanced Tissue enhanced cerebral cortex: 4.3;endometrium: 4.3;smooth muscle: 4.7;thyroid gland: 8.2 seminal vesicle: 2.4 GAS1 ENSG00000180447 Growth arrest-specific 1 9 86944363-86947189 Cancer-related genes, Predicted secreted proteins Evidence at protein level CAB024164, HPA036085, HPA066902 Approved Approved Nuclear speckles Thyroid cancer:1.13e-5 (unfavourable), Renal cancer:1.96e-5 (unfavourable), Colorectal cancer:1.55e-4 (unfavourable), Stomach cancer:8.26e-4 (unfavourable) Expressed in all Tissue enhanced endometrium: 110.4 smooth muscle: 73.6 GJC1 CX45, GJA7 ENSG00000182963 Gap junction protein, gamma 1, 45kDa 17 44798448-44830816 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA071788 Uncertain Nucleoli
Cell Junctions
Cytosol Renal cancer:3.55e-8 (unfavourable), Urothelial cancer:7.83e-4 (unfavourable) Expressed in all Tissue enhanced endometrium: 43.9;placenta: 50.9;smooth muscle: 48.2 seminal vesicle: 27.0 GLI1 GLI ENSG00000111087 GLI family zinc finger 1 12 57460135-57472262 Predicted intracellular proteins, Transcription factors Evidence at protein level CAB009460, HPA065172 Uncertain Supported Nucleoplasm
Cytosol Tissue enhanced Tissue enhanced cervix, uterine: 15.0;endometrium: 15.1 gallbladder: 8.5 GNLY D2S69E, LAG-2, LAG2, NKG5, TLA519 ENSG00000115523 Granulysin 2 85685175-85698854 Predicted intracellular proteins, Predicted secreted proteins, Transporters Evidence at protein level CAB025186, HPA058021 Supported Endometrial cancer:3.48e-5 (favourable), Melanoma:6.60e-5 (favourable), Renal cancer:1.50e-4 (unfavourable), Urothelial cancer:8.07e-4 (favourable) Expressed in all Tissue enhanced bone marrow: 153.1;endometrium: 113.5;spleen: 114.5 lung: 51.2 HAND2 bHLHa26, dHand, Hed, Thing2 ENSG00000164107 Heart and neural crest derivatives expressed 2 4 173524969-173530229 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA019591, CAB025576 Approved Supported Nucleoplasm
Vesicles Tissue enhanced Tissue enhanced endometrium: 83.7 smooth muscle: 77.6 HOXA10 HOX1, HOX1H ENSG00000253293 Homeobox A10 7 27170591-27180261 Predicted intracellular proteins, Transcription factors Evidence at protein level CAB019384 Approved Supported Nucleoplasm
Nuclear bodies Mixed Tissue enhanced endometrium: 116.3;smooth muscle: 67.0 prostate: 42.4 HOXA10-HOXA9 ENSG00000257184 7 27163535-27180013 Predicted intracellular proteins Evidence at transcript level Not detected Tissue enhanced endometrium: 1.0 prostate: 0.3 HOXA11 HOX1, HOX1I ENSG00000005073 Homeobox A11 7 27181510-27185223 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA006770, HPA035623 Supported Supported Nucleoplasm Renal cancer:2.57e-5 (unfavourable) Mixed Tissue enhanced endometrium: 96.0;smooth muscle: 67.7 cervix, uterine: 18.3 HOXD10 HOX4, HOX4D ENSG00000128710 Homeobox D10 2 176108790-176119942 Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA065871 Approved Nucleoplasm
Cytosol
Cytoplasmic bodies Renal cancer:1.92e-6 (unfavourable) Mixed Tissue enhanced endometrium: 48.0;smooth muscle: 24.9 kidney: 12.6 HOXD11 HOX4, HOX4F ENSG00000128713 Homeobox D11 2 176104216-176109754 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at transcript level HPA055155 Approved Nucleoplasm Mixed Tissue enhanced endometrium: 5.9 colon,smooth muscle: 1.6 HOXD4 HOX4, HOX4B ENSG00000170166 Homeobox D4 2 176151222-176153226 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA054383, HPA070349 Approved Validated Nucleus
Cell Junctions Tissue enhanced Tissue enhanced endometrium: 23.5;epididymis: 22.6 fallopian tube: 15.4 HOXD9 HOX4, HOX4C ENSG00000128709 Homeobox D9 2 176122720-176124937 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA068683 Supported Nucleus
Nucleoli Liver cancer:1.08e-5 (unfavourable), Colorectal cancer:8.25e-4 (unfavourable), Head and neck cancer:9.58e-4 (favourable) Expressed in all Tissue enhanced endometrium: 45.3 smooth muscle: 23.6 HTR1E 5-HT1E ENSG00000168830 5-hydroxytryptamine (serotonin) receptor 1E, G protein-coupled 6 86937306-87016683 G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA004931 Approved Not detected Tissue enhanced endometrium: 2.4;ovary: 4.9 cerebral cortex: 1.9 HTR2B 5-HT(2B), 5-HT2B ENSG00000135914 5-hydroxytryptamine (serotonin) receptor 2B, G protein-coupled 2 231108230-231125118 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level CAB011448, HPA012867, HPA063658 Approved Approved Nucleoplasm Mixed Tissue enhanced cervix, uterine: 31.1;endometrium: 30.0;smooth muscle: 23.0 adrenal gland: 19.1 IL11 AGIF, IL-11 ENSG00000095752 Interleukin 11 19 55364389-55370463 Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA044955 Uncertain Mitochondria Pancreatic cancer:7.50e-4 (unfavourable) Mixed Tissue enhanced appendix: 5.8;endometrium: 5.2;gallbladder: 4.9 placenta,skin: 1.7 INHBA ENSG00000122641 Inhibin, beta A 7 41685114-41703108 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA020031 Uncertain Renal cancer:7.91e-8 (unfavourable), Cervical cancer:1.46e-5 (unfavourable), Head and neck cancer:4.34e-4 (unfavourable), Lung cancer:7.72e-4 (unfavourable) Expressed in all Tissue enhanced endometrium: 28.7;gallbladder: 35.0 lung: 16.4 IRS4 IRS-4, PY160 ENSG00000133124 Insulin receptor substrate 4 X 108732482-108736409 Predicted secreted proteins Evidence at protein level HPA017372 Uncertain Mixed Tissue enhanced endometrium: 1.7;ovary: 4.4;thyroid gland: 2.1 cervix, uterine: 1.1 ITGA11 HsT18964 ENSG00000137809 Integrin, alpha 11 15 68296533-68432162 Predicted membrane proteins Evidence at protein level HPA051813 Uncertain Renal cancer:3.22e-7 (unfavourable) Mixed Tissue enhanced cervix, uterine: 54.4;endometrium: 52.2;smooth muscle: 74.7 epididymis: 22.7 KCNAB3 AKR6A9, KCNA3B ENSG00000170049 Potassium channel, voltage gated subfamily A regulatory beta subunit 3 17 7921859-7929803 Predicted intracellular proteins Evidence at protein level HPA077993 Approved Mitochondria Mixed Tissue enhanced endometrium: 14.5;smooth muscle: 8.5 cerebral cortex: 4.7 KCNG1 K13, KCNG, kH2, Kv6.1 ENSG00000026559 Potassium channel, voltage gated modifier subfamily G, member 1 20 51003656-51023129 Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA039530, HPA040024 Approved Validated Vesicles Tissue enhanced Tissue enhanced endometrium: 23.4;seminal vesicle: 17.9 placenta: 10.8 KIAA1644 ENSG00000138944 KIAA1644 22 44243667-44312851 Predicted membrane proteins Evidence at transcript level HPA051178 Uncertain Approved Vesicles
Cytosol Mixed Tissue enhanced cerebral cortex: 27.6;endometrium: 42.5;smooth muscle: 44.0 cervix, uterine: 19.1 KLHL13 BKLHD2, FLJ10262, KIAA1309 ENSG00000003096 Kelch-like family member 13 X 117897813-118117340 Predicted intracellular proteins Evidence at protein level HPA046039, HPA059901 Approved Approved Cytosol Mixed Tissue enhanced endometrium: 52.2 smooth muscle: 43.3 LINGO2 LERN3, LRRN6C ENSG00000174482 Leucine rich repeat and Ig domain containing 2 9 27948078-28670286 Predicted membrane proteins Evidence at transcript level HPA016633, CAB025361 Approved Mixed Tissue enhanced endometrium: 11.8;smooth muscle: 12.8 thyroid gland: 4.9 MEIS3 DKFZp547H236, MRG2 ENSG00000105419 Meis homeobox 3 19 47403124-47419523 Predicted intracellular proteins, Predicted secreted proteins, Transcription factors Evidence at protein level HPA046699 Uncertain Approved Nucleoplasm Renal cancer:1.78e-6 (unfavourable) Mixed Tissue enhanced endometrium: 82.2 cerebral cortex: 65.0 MEX3A RKHD4 ENSG00000254726 Mex-3 RNA binding family member A 1 156072013-156081998 Predicted intracellular proteins Evidence at protein level HPA062703 Supported Cytosol Liver cancer:9.23e-8 (unfavourable) Expressed in all Tissue enhanced endometrium: 5.9;ovary: 5.9 cerebral cortex: 4.1 MITF bHLHe32, MI, WS2, WS2A ENSG00000187098 Microphthalmia-associated transcription factor 3 69739435-69968337 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB002578, HPA003259 Supported Renal cancer:8.35e-10 (favourable) Group enriched Tissue enhanced cervix, uterine: 80.4;endometrium: 78.8 smooth muscle: 68.6 MMP3 STMY, STMY1 ENSG00000149968 Matrix metallopeptidase 3 11 102835801-102843803 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA007875 Uncertain Approved Vesicles Pancreatic cancer:4.09e-4 (unfavourable), Cervical cancer:9.73e-4 (unfavourable) Tissue enhanced Tissue enhanced appendix: 26.9;endometrium: 58.7 urinary bladder: 9.2 MOXD1 dJ248E1.1, DKFZP564G202, MOX ENSG00000079931 Monooxygenase, DBH-like 1 6 132296055-132401545 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA035740 Approved Approved Nucleoplasm
Cytosol Head and neck cancer:7.09e-5 (favourable), Stomach cancer:3.72e-4 (unfavourable) Expressed in all Tissue enhanced endometrium: 105.3;smooth muscle: 113.0 seminal vesicle: 53.1 NPAS4 bHLHe79, Le-PAS, NXF, PASD10 ENSG00000174576 Neuronal PAS domain protein 4 11 66421004-66426707 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA039255 Uncertain Not detected Tissue enhanced cerebral cortex: 4.1;endometrium: 1.9 smooth muscle: 1.5 OSR2 FLJ90037 ENSG00000164920 Odd-skipped related transciption factor 2 8 98944403-98952104 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA052425, HPA063486 Uncertain Approved Nucleus
Plasma membrane Head and neck cancer:2.44e-5 (favourable) Mixed Tissue enhanced endometrium: 204.6;fallopian tube: 143.0 ovary: 102.5 PAMR1 DKFZP586H2123, RAMP ENSG00000149090 Peptidase domain containing associated with muscle regeneration 1 11 35431823-35530300 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level Renal cancer:5.08e-5 (unfavourable), Stomach cancer:6.29e-4 (unfavourable) Expressed in all Tissue enhanced cervix, uterine: 86.5;endometrium: 91.9 placenta: 75.5 PCDHA2 ENSG00000204969 Protocadherin alpha 2 5 140794852-141012344 Predicted membrane proteins Evidence at protein level HPA035653 Uncertain Not detected Tissue enhanced endometrium: 1.0 cerebral cortex: 0.9 PCDHB7 PCDH-BETA7 ENSG00000113212 Protocadherin beta 7 5 141172619-141176383 Plasma proteins, Predicted membrane proteins Evidence at transcript level HPA059271 Approved Tissue enhanced Tissue enhanced endometrium: 6.6 smooth muscle: 4.4 PLK5 PLK5P, SgK384ps ENSG00000185988 Polo-like kinase 5 19 1524074-1535456 Enzymes, Predicted intracellular proteins Evidence at protein level HPA035024 Approved Mixed Tissue enhanced cervix, uterine: 4.5;endometrium: 4.7;testis: 6.9 epididymis: 3.3 PTGFR FP ENSG00000122420 Prostaglandin F receptor (FP) 1 78303884-78539749 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level Mixed Tissue enhanced endometrium: 30.3;smooth muscle: 25.4 urinary bladder: 13.3 RAMP1 ENSG00000132329 Receptor (G protein-coupled) activity modifying protein 1 2 237858893-237912114 FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA057814 Approved Nucleoplasm
Nuclear membrane Stomach cancer:1.68e-4 (unfavourable), Liver cancer:7.61e-4 (favourable) Expressed in all Tissue enhanced endometrium: 233.7 smooth muscle: 169.4 RPRM FLJ90327, REPRIMO ENSG00000177519 Reprimo, TP53 dependent G2 arrest mediator candidate 2 153477338-153478808 Predicted membrane proteins Evidence at protein level Group enriched Tissue enhanced cerebral cortex: 21.3;endometrium: 21.9 smooth muscle: 17.3 RSPO1 FLJ40906, RSPONDIN ENSG00000169218 R-spondin 1 1 37611350-37634923 Disease related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA046154 Uncertain Tissue enriched Tissue enhanced endometrium: 43.3;fallopian tube: 32.8 smooth muscle: 21.0 RSPO3 FLJ14440, THSD2 ENSG00000146374 R-spondin 3 6 127118604-127197765 Cancer-related genes, Predicted secreted proteins Evidence at protein level HPA029957 Approved Mixed Tissue enhanced endometrium: 102.8;smooth muscle: 102.3 placenta: 72.8 RXFP1 LGR7, RXFPR1 ENSG00000171509 Relaxin/insulin-like family peptide receptor 1 4 158315311-158653372 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA027067 Approved Tissue enriched Tissue enhanced cerebral cortex: 21.7;endometrium: 10.1 adrenal gland: 5.7 SERTM1 C13orf36 ENSG00000180440 Serine-rich and transmembrane domain containing 1 13 36673912-36697839 Predicted membrane proteins Evidence at protein level HPA054814, HPA070485 Uncertain Supported Vesicles Tissue enhanced Tissue enhanced cerebral cortex: 47.8;endometrium: 37.3;fallopian tube: 29.3 smooth muscle: 24.5 SLC7A3 ATRC3, CAT-3, FLJ14541 ENSG00000165349 Solute carrier family 7 (cationic amino acid transporter, y+ system), member 3 X 70925582-70931125 Predicted membrane proteins, Transporters Evidence at protein level HPA003629 Approved Tissue enriched Tissue enhanced endometrium: 7.8;prostate: 9.6;seminal vesicle: 7.4 smooth muscle: 4.0 SLITRK3 KIAA0848 ENSG00000121871 SLIT and NTRK-like family, member 3 3 165186720-165197109 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA017636 Approved Mitochondria Tissue enriched Tissue enhanced cerebral cortex: 17.4;endometrium: 12.4 fallopian tube: 9.7 SNCAIP SYPH1 ENSG00000064692 Synuclein, alpha interacting protein 5 122311354-122464219 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA064687 Uncertain Supported Cytoplasmic bodies Mixed Tissue enhanced endometrium: 30.0;ovary: 43.3 cervix, uterine: 26.0 SOX17 ENSG00000164736 SRY (sex determining region Y)-box 17 8 54457935-54460888 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB025594, HPA068399 Supported Approved Nucleoplasm Endometrial cancer:2.76e-4 (favourable) Group enriched Tissue enhanced cervix, uterine: 30.1;endometrium: 32.1;fallopian tube: 30.1 adipose tissue: 14.7 SP5 ENSG00000204335 Sp5 transcription factor 2 170715351-170718078 Predicted intracellular proteins, Transcription factors Evidence at transcript level HPA074123 Approved Nucleus
Nucleoli Mixed Tissue enhanced endometrium: 3.9 stomach: 2.4 SPON2 DIL1 ENSG00000159674 Spondin 2, extracellular matrix protein 4 1166932-1208962 Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA040170, HPA066095 Uncertain Approved Vesicles Endometrial cancer:2.03e-4 (favourable), Urothelial cancer:9.22e-4 (unfavourable) Tissue enriched Tissue enhanced endometrium: 105.3;prostate: 96.8 cervix, uterine: 53.6 SYTL4 ENSG00000102362 Synaptotagmin-like 4 X 100674491-100732123 Predicted intracellular proteins Evidence at protein level HPA001475, HPA001589 Approved Approved Nucleoplasm
Microtubule organizing center
Cytosol Renal cancer:2.09e-4 (unfavourable) Expressed in all Tissue enhanced endometrium: 71.4;ovary: 83.9 smooth muscle: 48.7 TCF23 bHLHa24, OUT ENSG00000163792 Transcription factor 23 2 27149004-27156974 Predicted intracellular proteins, Transcription factors Evidence at transcript level Mixed Tissue enhanced endometrium: 33.7;ovary: 22.6;smooth muscle: 30.5 fallopian tube: 13.9 TGFB1I1 ARA55, Hic-5, TSC-5 ENSG00000140682 Transforming growth factor beta 1 induced transcript 1 16 31471585-31477960 Predicted intracellular proteins Evidence at protein level CAB020844 Approved Supported Focal adhesion sites
Cytosol Renal cancer:6.06e-8 (unfavourable), Urothelial cancer:7.73e-5 (unfavourable) Expressed in all Tissue enhanced endometrium: 139.7;smooth muscle: 151.9 seminal vesicle: 109.6 TMEM158 p40BBp, RIS1 ENSG00000249992 Transmembrane protein 158 (gene/pseudogene) 3 45224466-45226278 Predicted membrane proteins Evidence at transcript level Renal cancer:5.42e-9 (unfavourable), Prostate cancer:6.43e-5 (favourable) Mixed Tissue enhanced endometrium: 32.5;seminal vesicle: 31.8 smooth muscle: 25.4 TMEM200A KIAA1913, TTMC ENSG00000164484 Transmembrane protein 200A 6 130365734-130443063 Predicted membrane proteins Evidence at protein level HPA014396 Uncertain Renal cancer:3.92e-4 (favourable) Mixed Tissue enhanced endometrium: 64.8 smooth muscle: 29.0 TMEM200B TTMB ENSG00000253304 Transmembrane protein 200B 1 29119428-29123935 Predicted membrane proteins Evidence at transcript level HPA055254 Uncertain Mixed Tissue enhanced endometrium: 68.0 seminal vesicle: 52.6 TNFAIP8L3 FLJ41287 ENSG00000183578 Tumor necrosis factor, alpha-induced protein 8-like 3 15 51056598-51105276 Predicted intracellular proteins Evidence at protein level HPA048372 Uncertain Urothelial cancer:3.51e-4 (unfavourable) Expressed in all Tissue enhanced endometrium: 118.6;smooth muscle: 105.4 fallopian tube: 33.7 TRPC4 HTRP4, TRP4 ENSG00000133107 Transient receptor potential cation channel, subfamily C, member 4 13 37636636-37870425 Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level Mixed Tissue enhanced endometrium: 18.5;seminal vesicle: 12.0;smooth muscle: 18.2 prostate: 10.7 TSHB ENSG00000134200 Thyroid stimulating hormone, beta 1 115029824-115034309 Predicted secreted proteins Evidence at protein level Not detected Tissue enhanced endometrium: 1.7 seminal vesicle: 1.0 TSPAN2 FLJ12082, TSN2, TSPAN-2 ENSG00000134198 Tetraspanin 2 1 115048011-115089500 Predicted membrane proteins Evidence at protein level HPA015640 Uncertain Approved Nucleoplasm Renal cancer:8.48e-7 (unfavourable), Endometrial cancer:8.89e-4 (unfavourable) Mixed Tissue enhanced endometrium: 71.2;smooth muscle: 64.0 seminal vesicle: 40.1 TWIST1 ACS3, bHLHa38, BPES2, BPES3, CRS, CRS1, H-twist, SCS, TWIST ENSG00000122691 Twist family bHLH transcription factor 1 7 19020991-19117672 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level Mixed Tissue enhanced adipose tissue: 22.7;endometrium: 30.7 placenta: 17.2 WNT5A hWNT5A ENSG00000114251 Wingless-type MMTV integration site family, member 5A 3 55465715-55490539 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level Colorectal cancer:2.94e-5 (favourable) Expressed in all Tissue enhanced endometrium: 46.3 urinary bladder: 36.5 WT1 AWT1, GUD, WAGR, WIT-2 ENSG00000184937 Wilms tumor 1 11 32387775-32435630 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB000327, HPA035717, HPA053848 Supported Supported Nucleoplasm Tissue enriched Tissue enhanced endometrium: 112.0;fallopian tube: 123.1;smooth muscle: 78.9 testis: 53.8